Web Exclusives

On May 27, 2026, the FDA approved pivekimab sunirine-pvzy (Decnupaz) for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare hematologic malignancy.

On March 13, 2026, the Maryland Insurance Administration (MIA) fined Cigna $80,000 and ordered the insurer to stop automatically downcoding evaluation and management (E/M) claims.

The financial aspect of cancer care deeply affects the patient’s experience economically, physically, and psychologically.

On March 11, 2026, the FDA announced the launch of the FDA Adverse Event Monitoring System (AEMS), a unified platform designed to modernize and streamline the agency’s analysis of adverse event reports.

On February 19, 2026, the FDA approved the combination of acalabrutinib (Calquence) and venetoclax (Venclexta) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Sweeping insurance and policy changes are poised to reshape how patients access and maintain coverage across Medicare, the Marketplace, Medicaid, and the Supplemental Nutrition Assistance Program (SNAP).

Imagine you are a healthcare provider seeing a complex patient with symptoms that could point to hundreds of conditions.

Advances in precision medicine and biomarker testing are transforming lung cancer treatment, offering hope through targeted therapies and innovative approaches.

With major reimbursement and coverage changes occurring in 2026, oncology practices are closely watching federal policy developments that could affect everything from prior authorization workflows to drug reimbursement and patient coverage stability.

It started with a bit of blood.